Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.